Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Data Update: Innovative ART Strategies

Michelle S. Cespedes, MD, MS, reviews new data on emerging agents such as islatravir and lenacapavir.
W. David Hardy, MD
Program Director
Michelle S. Cespedes, MD, MS
Gregory Huhn, MD, MPHTM
David A. Wohl, MD
Released: October 22, 2020

Information on this Educational Activity

Program Director

W. David Hardy, MD

Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine

Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California

W. David Hardy, MD, has disclosed that he has received consulting fees from Enochian Biosciences, Gilead Sciences, Merck, and ViiV/GlaxoSmithKline.

Faculty

Michelle S. Cespedes, MD, MS

Associate Professor of Medicine
Division of Infectious Disease
Department of Medicine
Icahn School of Medicine at Mount Sinai
Attending Physician
Mount Sinai Medical Center
New York, New York

Michelle S. Cespedes, MD, MS, has disclosed that she has received consulting fees from Gilead Sciences and ViiV Healthcare.
Gregory Huhn, MD, MPHTM

Associate Professor
Department of Infectious Diseases
Rush University Medical Center
Senior Director of HIV Services
Department of Infectious Diseases
Cook County Health
Chicago, Illinois

Gregory Huhn, MD, MPH, has disclosed that he has received funds for research support from Gilead Sciences, Janssen, Lilly, Proteus, and ViiV; consulting fees from Lilly and Janssen; and has served on advisory boards or panels for Gilead Sciences, Janssen, and ViiV.
David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases
Clinical Trials Unit
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

David A. Wohl, MD, has disclosed that he has received funds for research support from Gilead Sciences, Merck, and ViiV and consulting fees from Gilead Sciences, Janssen, Merck, and ViiV.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Tiffany Hensley-McBain, PhD

Scientific Director

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa has no relevant conflicts of interest to report.

Target Audience

This program is intended for physicians, clinical pharmacists, nurses and other healthcare providers who care for patients with HIV.

Goal

The goal of this activity is to enhance clinicians' competence in addressing the most important and most current challenges in HIV disease management by providing a tightly focused update on recent advances and key issues encountered in the clinic.

Program Medium

This program has been made available online.

Related Content

Safety and efficacy of broadly neutralizing antibody VRC01 with early ART in infants with HIV, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Opciones de cuidado clínico (CCO) presenta a la Dra. Alicia Piñeirúa que explica los principales factores que hay que tener en cuenta a la hora de optimizar el tratamiento antirretroviral en el marco de la supresión viral en pacientes que viven con el VIH y la osteopenia

person default Alicia Piñeirúa Menéndez, MD, MPH Released: August 2, 2022

Expert insights on new, emerging, and potential future long-acting antiretroviral agents for HIV treatment and prevention, from Clinical Care Options (CCO)

Expert preview of data from the AIDS 2022 conference, including HIV cure, coinfections, long-acting PrEP, global progress toward UNAIDS 95-95-95 targets, and equity in healthcare access, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: July 13, 2022

Video Chapters


Provided by University of South Florida

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings